Insights from BCC Research

Biomarkers are at the core of identifying any disease or biological condition, and the discovery of new biomarkers has enormous commercial potential. While aiding in diagnostics, prognostics and companion diagnostics, biomarkers are becoming essential tools in one critical process: drug development. As a result, the biomarkers market has been rapidly expanding in recent years, according to a recent webinar led by BCC Research analyst Marianna Tcherpakov, PhD.

The following is an excerpt from BCC Research Report “Synthetic Biology: Global Markets” by John Bergin.

The global market for biological safety testing is anticipating brisk growth in coming years owing to the growth of personalized medicines, patent expiration of brand-name biologics, and the development of new cell lines that express specific biomarkers for disease states, according to a new report from BCC Research. The market’s compound annual growth rate (CAGR) is forecast to be 20.09% through 2022.